Source-grounded facts extracted from PMV Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PMV Pharmaceuticals, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2026-06-04 meeting.
“The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
PMV Pharmaceuticals, Inc. shareholders approved Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-04 meeting.
“The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 22, 2026 (the “Proxy Statement”).”
PMV Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2026-06-04 meeting.
“The Company’s stockholders elected the two persons listed below as Class III Directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal.”
PMV Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.
“Net loss for the quarter ended March 31, 2026, was $18 million compared to $17.4 million for the quarter ended March 31, 2025.”
PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $77.7 million.
“On March 6, 2026, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”
PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the quarter ended March 31, 2024, was $15.3 million.
“PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
PMV Pharmaceuticals, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 3.
“Net loss for the year ended December 31, 2023, was $69.0 million compared to $73.3 million for the year ended December 31, 2022.”
PMV Pharmaceuticals, Inc. announced a restructuring with charges of approximately $1.4 million (approximately 30% of the Company’s employees).
“development for its lead product candidate, PC14586. As a result of the reduction in force, the Company expects to incur aggregate non-recurring charges of approximately $1.4 million, consisting primarily of employee severance and benefit costs associated with the restructuring. The Company expects that most of these charges will be cash expenditures and that”
Leila Alland changed role as Chief Medical Officer at PMV Pharmaceuticals, Inc..
“Also on January 5, 2024, the Company announced that Leila Alland, M.D., the Company’s Chief Medical Officer (“ CMO ”), will transition from her role as CMO, effective on January 5, 2024.”
Winston Kung changed role as Chief Operating Officer and Chief Financial Officer at PMV Pharmaceuticals, Inc..
“On January 5, 2024, the Company also announced that Winston Kung, the Company’s current Chief Operating Officer (“ COO ”) and CFO, will transition from his role as COO and CFO, effective January 4, 2024.”
Michael Carulli was appointed as Chief Financial Officer at PMV Pharmaceuticals, Inc..
“On January 5, 2024, PMV Pharmaceuticals, Inc. (the “ Company ”) announced the appointment of Michael Carulli as Chief Financial Officer (“ CFO ”), principal financial officer and principal accounting officer of the Company”
PMV Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2023.
“On November 9, 2023, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.”
PMV Pharmaceuticals, Inc. reported Six months ended June 30, 2023 results: net income -$36.6 million.
“Net loss for the six months ended June 30, 2023, was $36.6 million compared to $35.7 million for the six months ended June 30, 2022.”
PMV Pharmaceuticals, Inc. shareholders approved Ratification of Independent Registered Public Accounting Firm at the 2023-06-08 meeting.
“Proposal 3. Ratification of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: FOR AGAINST ABSTAIN 39,864,451 2,087 538”
PMV Pharmaceuticals, Inc. shareholders approved Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2023-06-08 meeting.
“Proposal 2. Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on a non-binding advisory basis, the compensation paid to its named executive officers as described in the Company’s definitive proxy statement on Schedule 14A, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2023 (the “Proxy Statement”). The final voting results are as follows: FOR AGAINST ABSTAIN BROKER NON-VOTE 34,537,890 836,543 1,065 4,491,578”
PMV Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-08 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class III Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal. The final voting results are as follows: FOR WITHHELD BROKER NON-VOTE Richard Heyman, Ph.D. 28,709,696 6,665,802 4,491,578 David H. Mack, Ph.D. 35,181,696 193,802 4,491,578 Laurie Stelzer 34,128,780 1,246,718 4,491,578”
PMV Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023, was $19.1 million.
“PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2023.”
PMV Pharmaceuticals, Inc.: Amended and restated bylaws to update advance notice procedures, conform to DGCL amendments, and make ministerial changes (effective 2023-06-08).
“to be effective on June 8, 2023, the date of the Company’s 2023 annual meeting of stockholders.”
PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022, was $73.3 million.
“Net loss for the year ended December 31, 2022, was $73.3 million”
PMV Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.
“PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.”
Carol Gallagher was appointed as Director at PMV Pharmaceuticals, Inc..
“On November 3, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Carol Gallagher, Pharm.D. as a Class I director of the Company to fill the vacancy of Dr. Schroeder’s seat on the Board of the Company.”
Thilo Schroeder resigned as Director at PMV Pharmaceuticals, Inc..
“On November 3, 2022, Thilo Schroeder, Ph.D., notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effective on that date.”
Kirsten Flowers was appointed as Director at PMV Pharmaceuticals, Inc..
“On January 5, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of the Company unanimously approved the appointment of Kirsten Flowers as a director and Class I director of the Company to fill the vacancy of Dr. Thompson’s seat on the Board of the Company.”
Peter Thompson resigned as Director at PMV Pharmaceuticals, Inc..
“On January 5, 2022, Peter Thompson, M.D. notified PMV Pharmaceuticals, Inc. (the “Company”) of his decision to resign as a member of the Board of Directors (the “Board”), which resignation was effected on January 5, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.